Physician profile
Nicholas Farina
NPI 1013901164
$3,574.02
in general payments reported to CMS, 2019-2025
27 companies · $933 in 2025
The $933 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $109 · 2021: $222 · 2022: $384 · 2023: $681 · 2024: $792 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $757.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $438.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $366.59 | 2022-2025 | |
| Novo Nordisk INC | $344.92 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $306.15 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $228.92 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.08 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $151.80 | 2019-2025 | Spravato |
| Corium, LLC | $103.61 | 2023 | Adlarity |
| Sanofi-Aventis U.S. LLC | $100.06 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $62.95 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $58.30 | 2022-2024 | Ultomiris |
| Averitas Pharma INC. | $54.22 | 2025 | Qutenza |
| Exact Sciences Corporation | $49.50 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $46.47 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.35 | 2023-2024 | |
| Amarin Pharma, INC. | $37.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.23 | 2020-2025 | Xifaxan |
| Medtronic, INC. | $31.25 | 2022-2023 | Intellis Adaptivestim |
| Astellas Pharma US INC | $29.48 | 2023-2024 | Veozah |
| Abbott Laboratories | $28.66 | 2021-2022 | |
| Insulet Corporation | $24.42 | 2025 | Omnipod |
| Eisai INC. | $22.60 | 2025 | |
| Abbvie INC. | $22.39 | 2025 | |
| Edwards Lifesciences Corporation | $20.29 | 2024 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $13.48 | 2019 | |
| Kyowa Kirin, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Farina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.